van 't Veer LJ - Search Results

1

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF^V600E colorectal tumors.

Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Coppé JP. Ruiz-Saenz A, et al. Nat Cancer. 2023 Feb;4(2):240-256. doi: 10.1038/s43018-022-00508-5. Epub 2023 Feb 9. Nat Cancer. 2023. PMID: 36759733 Free PMC article.

2

Two genes encode factors with NF-kappa B- and H2TF1-like DNA-binding properties.

Rustgi AK, Van 't Veer LJ, Bernards R. Rustgi AK, et al. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8707-10. doi: 10.1073/pnas.87.22.8707. Proc Natl Acad Sci U S A. 1990. PMID: 2247438 Free PMC article.

3

E2F-5, a new E2F family member that interacts with p130 in vivo.

Hijmans EM, Voorhoeve PM, Beijersbergen RL, van 't Veer LJ, Bernards R. Hijmans EM, et al. Mol Cell Biol. 1995 Jun;15(6):3082-9. doi: 10.1128/MCB.15.6.3082. Mol Cell Biol. 1995. PMID: 7760804 Free PMC article.

4

Gene expression profiling predicts clinical outcome of breast cancer.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. van 't Veer LJ, et al. Nature. 2002 Jan 31;415(6871):530-6. doi: 10.1038/415530a. Nature. 2002. PMID: 11823860

5

Enabling personalized cancer medicine through analysis of gene-expression patterns.

van't Veer LJ, Bernards R. van't Veer LJ, et al. Nature. 2008 Apr 3;452(7187):564-70. doi: 10.1038/nature06915. Nature. 2008. PMID: 18385730 Review.

6

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.

Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, van't Veer L, Salazar R, Bernards R, Capella G. Tian S, et al. Gut. 2013 Apr;62(4):540-9. doi: 10.1136/gutjnl-2012-302423. Epub 2012 Jul 14. Gut. 2013. PMID: 22798500 Free PMC article.

7

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ. Daemen A, et al. Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9. Breast Cancer Res Treat. 2012. PMID: 22875744 Free PMC article.

8

A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.

Mittempergher L, Saghatchian M, Wolf DM, Michiels S, Canisius S, Dessen P, Delaloge S, Lazar V, Benz SC, Tursz T, Bernards R, van't Veer LJ. Mittempergher L, et al. Mol Oncol. 2013 Oct;7(5):987-99. doi: 10.1016/j.molonc.2013.07.006. Epub 2013 Jul 17. Mol Oncol. 2013. PMID: 23910573 Free PMC article.

9

Long-term impact of the 70-gene signature on breast cancer outcome.

Drukker CA, van Tinteren H, Schmidt MK, Rutgers EJ, Bernards R, van de Vijver MJ, Van't Veer LJ. Drukker CA, et al. Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21. Breast Cancer Res Treat. 2014. PMID: 24445566 Free PMC article.

10

Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.

Wolf DM, Lenburg ME, Yau C, Boudreau A, van 't Veer LJ. Wolf DM, et al. PLoS One. 2014 Feb 7;9(2):e88309. doi: 10.1371/journal.pone.0088309. eCollection 2014. PLoS One. 2014. PMID: 24516633 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

310 results

Search Page